村上 孝作

最終更新日時: 2019/06/17 15:13:00

印刷する

氏名(漢字/フリガナ/アルファベット表記)
村上 孝作/ムラカミ コウサク/Murakami, Kousaku
所属部署・職名(部局/所属/講座等/職名)
医学部附属病院/内科(免疫・膠原病内科)/助教
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
博士(医学) 京都大学 Kyoto University
プロフィール
(日本語)
リウマチ性疾患の診療及び研究を行っている。
(英語)
Dedicating on clinical and research works about rheumatology
researchmap URL
https://researchmap.jp/rjfnq826
研究テーマ
(日本語)
脂質による慢性炎症がリウマチ性疾患に及ぼす影響について
(英語)
Influence of lipid mediator on inflammatory response in rheumatic disorders
研究概要
(日本語)
ドコサヘキサエン酸あるいはエイコサペンタエン酸といったω-3系脂肪酸の代謝産物は炎症を収束させるメディエーターであることが近年明らかとなっている。これらの脂質メディエーターが関節リウマチをはじめとしたリウマチ性疾患に果たす役割を研究している。
(英語)
Omega-3 fatty acid promotes resolution of inflammation. I am currently studying the infuluence of these medeiators on rhuematic disorders.
研究分野(キーワード)
キーワード(日本語) キーワード(英語)
リウマチ学 Rheumatoogy
関節リウマチ Rheumatoid Arthritis
慢性炎症 Chronic Inflammation
食習慣 Dietary Habit
自己抗体 Autoantibody
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Nakagami Y, Sugihara G, Takei N, Fujii T, Hashimoto M, Murakami K, Furu M, Ito H, Uda M, Torii M, Nin K, Murai T, Mimori T Nakagami Y, Sugihara G, Takei N, Fujii T, Hashimoto M, Murakami K, Furu M, Ito H, Uda M, Torii M, Nin K, Murai T, Mimori T Nakagami Y, Sugihara G, Takei N, Fujii T, Hashimoto M, Murakami K, Furu M, Ito H, Uda M, Torii M, Nin K, Murai T, Mimori T Effect of physical state on pain mediated through emotional health in rheumatoid arthritis. Effect of physical state on pain mediated through emotional health in rheumatoid arthritis. Effect of physical state on pain mediated through emotional health in rheumatoid arthritis. Arthritis care & research Arthritis care & research Arthritis care & research 2018/10 公開
Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Annals of the rheumatic diseases Annals of the rheumatic diseases Annals of the rheumatic diseases 2018/10 公開
Murakami K, Mimori T Murakami K, Mimori T Murakami K, Mimori T Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders. Internal medicine (Tokyo, Japan) Internal medicine (Tokyo, Japan) Internal medicine (Tokyo, Japan) 2018/08 公開
Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern rheumatology, 28, 4, 642-648 Modern rheumatology, 28, 4, 642-648 Modern rheumatology, 28, 4, 642-648 2018/07 公開
Okabe N, Ohmura K, Katayama M, Akizuki S, Carpino N, Murakami K, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Tanaka M, Mimori T Okabe N, Ohmura K, Katayama M, Akizuki S, Carpino N, Murakami K, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Tanaka M, Mimori T Okabe N, Ohmura K, Katayama M, Akizuki S, Carpino N, Murakami K, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Tanaka M, Mimori T Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Modern rheumatology, 28, 4, 626-636 Modern rheumatology, 28, 4, 626-636 Modern rheumatology, 28, 4, 626-636 2018/07 公開
Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, Ohmura K, Ishii H, Nakata K, Mimori T Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, Ohmura K, Ishii H, Nakata K, Mimori T Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, Ohmura K, Ishii H, Nakata K, Mimori T Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Modern rheumatology, 28, 4, 724-729 Modern rheumatology, 28, 4, 724-729 Modern rheumatology, 28, 4, 724-729 2018/07 公開
Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD study investigators. Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD study investigators. Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD study investigators. Predictive factors for structural remission using abatacept: Results from the ABROAD study. Predictive factors for structural remission using abatacept: Results from the ABROAD study. Predictive factors for structural remission using abatacept: Results from the ABROAD study. Modern rheumatology, 1-7 Modern rheumatology, 1-7 Modern rheumatology, 1-7 2018/06 公開
村上 孝作 村上 孝作 Murakami Kosaku 関節リウマチにおけるアバタセプトの骨破壊抑制効果について 関節リウマチにおけるアバタセプトの骨破壊抑制効果について Predictive factors for structural remission using abatacept: results from the ABROAD study. Mod Rheumatol Mod Rheumatol Mod Rheumatol 2018/05 英語 研究論文(学術雑誌) 公開
Murakami K, Mimori T Murakami K, Mimori T Murakami K, Mimori T [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The Pathophysiology in Rheumatoid Arthritis.] [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The Pathophysiology in Rheumatoid Arthritis.] [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The Pathophysiology in Rheumatoid Arthritis.] Clinical calcium, 28, 5, 595-600 Clinical calcium, 28, 5, 595-600 Clinical calcium, 28, 5, 595-600 2018 公開
Nakajima T, Yoshifuji H, Shimizu M, Kitagori K, Murakami K, Nakashima R, Imura Y, Tanaka M, Ohmura K, Matsuda F, Terao C, Mimori T Nakajima T, Yoshifuji H, Shimizu M, Kitagori K, Murakami K, Nakashima R, Imura Y, Tanaka M, Ohmura K, Matsuda F, Terao C, Mimori T Nakajima T, Yoshifuji H, Shimizu M, Kitagori K, Murakami K, Nakashima R, Imura Y, Tanaka M, Ohmura K, Matsuda F, Terao C, Mimori T A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis research & therapy, 19, 1, 197 Arthritis research & therapy, 19, 1, 197 Arthritis research & therapy, 19, 1, 197 2017/09 公開
Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, Kuramoto N, Ito S, Satoh J, Tanaka M, Fujii T, Mimori T, Ohmura K Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, Kuramoto N, Ito S, Satoh J, Tanaka M, Fujii T, Mimori T, Ohmura K Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, Kuramoto N, Ito S, Satoh J, Tanaka M, Fujii T, Mimori T, Ohmura K Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases. Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases. Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases. The Journal of rheumatology, 44, 9, 1384-1388 The Journal of rheumatology, 44, 9, 1384-1388 The Journal of rheumatology, 44, 9, 1384-1388 2017/09 公開
Takeuchi Y, Murakami K, Kuramoto N, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Ohmura K, Mimori T Takeuchi Y, Murakami K, Kuramoto N, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Ohmura K, Mimori T Takeuchi Y, Murakami K, Kuramoto N, Nakashima R, Hashimoto M, Imura Y, Yoshifuji H, Ohmura K, Mimori T Clinical Images: Chronic Nonbacterial Osteomyelitis. Clinical Images: Chronic Nonbacterial Osteomyelitis. Clinical Images: Chronic Nonbacterial Osteomyelitis. Arthritis & rheumatology (Hoboken, N.J.), 69, 8, 1660 Arthritis & rheumatology (Hoboken, N.J.), 69, 8, 1660 Arthritis & rheumatology (Hoboken, N.J.), 69, 8, 1660 2017/08 公開
Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Scientific reports, 7, 1, 6911 Scientific reports, 7, 1, 6911 Scientific reports, 7, 1, 6911 2017/07 公開
Nakabo S, Hashimoto M, Ito S, Furu M, Ito H, Fujii T, Yoshifuji H, Imura Y, Nakashima R, Murakami K, Kuramoto N, Tanaka M, Satoh J, Ishigami A, Morita S, Mimori T, Ohmura K Nakabo S, Hashimoto M, Ito S, Furu M, Ito H, Fujii T, Yoshifuji H, Imura Y, Nakashima R, Murakami K, Kuramoto N, Tanaka M, Satoh J, Ishigami A, Morita S, Mimori T, Ohmura K Nakabo S, Hashimoto M, Ito S, Furu M, Ito H, Fujii T, Yoshifuji H, Imura Y, Nakashima R, Murakami K, Kuramoto N, Tanaka M, Satoh J, Ishigami A, Morita S, Mimori T, Ohmura K Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Rheumatology (Oxford, England), 56, 7, 1217-1226 Rheumatology (Oxford, England), 56, 7, 1217-1226 Rheumatology (Oxford, England), 56, 7, 1217-1226 2017/07 公開
Hiwa R, Ohmura K, Nakabo S, Terao C, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Hashimoto M, Furu M, Ito H, Fujii T, Mimori T Hiwa R, Ohmura K, Nakabo S, Terao C, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Hashimoto M, Furu M, Ito H, Fujii T, Mimori T Hiwa R, Ohmura K, Nakabo S, Terao C, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Hashimoto M, Furu M, Ito H, Fujii T, Mimori T Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive. International journal of rheumatic diseases, 20, 6, 731-736 International journal of rheumatic diseases, 20, 6, 731-736 International journal of rheumatic diseases, 20, 6, 731-736 2017/06 公開
Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. Journal of autoimmunity, 77, 116-122 Journal of autoimmunity, 77, 116-122 Journal of autoimmunity, 77, 116-122 2017/02 公開
Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD Study Investigators. Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD Study Investigators. Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, ABROAD Study Investigators. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. The Journal of rheumatology, 43, 11, 1974-1983 The Journal of rheumatology, 43, 11, 1974-1983 The Journal of rheumatology, 43, 11, 1974-1983 2016/11 公開
Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP, Nakajima T, Ohmura K, Kawabata D, Yukawa N, Imura Y, Murakami K, Nakashima R, Usui T, Fujii T, Sakai K, Yanagita M, Hirayama Y, Mimori T Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP, Nakajima T, Ohmura K, Kawabata D, Yukawa N, Imura Y, Murakami K, Nakashima R, Usui T, Fujii T, Sakai K, Yanagita M, Hirayama Y, Mimori T Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP, Nakajima T, Ohmura K, Kawabata D, Yukawa N, Imura Y, Murakami K, Nakashima R, Usui T, Fujii T, Sakai K, Yanagita M, Hirayama Y, Mimori T Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. PloS one, 11, 12, e0167141 PloS one, 11, 12, e0167141 PloS one, 11, 12, e0167141 2016 公開
Yamakawa N, Oe K, Yukawa N, Murakami K, Nakashima R, Imura Y, Yoshifuji H, Ohmura K, Miura Y, Tomosugi N, Kawabata H, Takaori-Kondo A, Mimori T Yamakawa N, Oe K, Yukawa N, Murakami K, Nakashima R, Imura Y, Yoshifuji H, Ohmura K, Miura Y, Tomosugi N, Kawabata H, Takaori-Kondo A, Mimori T Yamakawa N, Oe K, Yukawa N, Murakami K, Nakashima R, Imura Y, Yoshifuji H, Ohmura K, Miura Y, Tomosugi N, Kawabata H, Takaori-Kondo A, Mimori T A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts. A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts. A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts. Internal medicine (Tokyo, Japan), 55, 18, 2697-2701 Internal medicine (Tokyo, Japan), 55, 18, 2697-2701 Internal medicine (Tokyo, Japan), 55, 18, 2697-2701 2016 公開
Murakami K Murakami K Murakami K Potential of specialized pro-resolving lipid mediators against rheumatic diseases. Potential of specialized pro-resolving lipid mediators against rheumatic diseases. Potential of specialized pro-resolving lipid mediators against rheumatic diseases. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 3, 155-163 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 3, 155-163 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 3, 155-163 2016 公開
Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A, Hashimoto M, Murakami K, Imura Y, Yukawa N, Yoshifuji H, Fujii T, Takaori-Kondo A, Mimori T Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A, Hashimoto M, Murakami K, Imura Y, Yukawa N, Yoshifuji H, Fujii T, Takaori-Kondo A, Mimori T Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A, Hashimoto M, Murakami K, Imura Y, Yukawa N, Yoshifuji H, Fujii T, Takaori-Kondo A, Mimori T Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 1, 64-71 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 1, 64-71 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 39, 1, 64-71 2016 公開
Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Yoshida S, Furu M, Hashimoto M, Ito H, Fujii T, Ohmura K, Murakami K, Takahashi M, Hamaguchi M, Tabara Y, Taniguchi A, Momohara S, Raychaudhuri S, Allaart CF, Yamanaka H, Mimori T, Matsuda F Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Yoshida S, Furu M, Hashimoto M, Ito H, Fujii T, Ohmura K, Murakami K, Takahashi M, Hamaguchi M, Tabara Y, Taniguchi A, Momohara S, Raychaudhuri S, Allaart CF, Yamanaka H, Mimori T, Matsuda F Terao C, Yamakawa N, Yano K, Markusse IM, Ikari K, Yoshida S, Furu M, Hashimoto M, Ito H, Fujii T, Ohmura K, Murakami K, Takahashi M, Hamaguchi M, Tabara Y, Taniguchi A, Momohara S, Raychaudhuri S, Allaart CF, Yamanaka H, Mimori T, Matsuda F Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 67, 12, 3113-3123 Arthritis & rheumatology (Hoboken, N.J.), 67, 12, 3113-3123 Arthritis & rheumatology (Hoboken, N.J.), 67, 12, 3113-3123 2015/12 公開
Ishikawa Y, Usui T, Shiomi A, Shimizu M, Murakami K, Mimori T Ishikawa Y, Usui T, Shiomi A, Shimizu M, Murakami K, Mimori T Ishikawa Y, Usui T, Shiomi A, Shimizu M, Murakami K, Mimori T Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice. Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice. Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice. European journal of immunology, 44, 11, 3453-3463 European journal of immunology, 44, 11, 3453-3463 European journal of immunology, 44, 11, 3453-3463 2014/11 公開
Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. Journal of immunology (Baltimore, Md. : 1950), 193, 2, 849-859 Journal of immunology (Baltimore, Md. : 1950), 193, 2, 849-859 Journal of immunology (Baltimore, Md. : 1950), 193, 2, 849-859 2014/07 公開
Murakami K, Ioan-Facsinay A, Toes R, Kloppenburg M, Huizinga T Murakami K, Ioan-Facsinay A, Toes R, Kloppenburg M, Huizinga T Murakami K, Ioan-Facsinay A, Toes R, Kloppenburg M, Huizinga T P2-006  profiles of receptors for specialized lipid mediators on synoviocyte from osteoarthritis. P2-006  profiles of receptors for specialized lipid mediators on synoviocyte from osteoarthritis. P2-006  profiles of receptors for specialized lipid mediators on synoviocyte from osteoarthritis. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 37, 4, 338b Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 37, 4, 338b Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 37, 4, 338b 2014 公開
Kitai Y, Murakami K, Yoshifuji H, Yukawa N, Kawabata D, Ohmura K, Fujii T, Mimori T Kitai Y, Murakami K, Yoshifuji H, Yukawa N, Kawabata D, Ohmura K, Fujii T, Mimori T Kitai Y, Murakami K, Yoshifuji H, Yukawa N, Kawabata D, Ohmura K, Fujii T, Mimori T A case of Behçet's disease developing after poststreptococcal acute glomerulonephritis. A case of Behçet's disease developing after poststreptococcal acute glomerulonephritis. A case of Behçet's disease developing after poststreptococcal acute glomerulonephritis. Modern rheumatology, 23, 6, 1221-1225 Modern rheumatology, 23, 6, 1221-1225 Modern rheumatology, 23, 6, 1221-1225 2013/11 公開
Terao C, Yoshifuji H, Ohmura K, Murakami K, Kawabata D, Yurugi K, Tazaki J, Kinoshita H, Kimura A, Akizuki M, Kawaguchi Y, Yamanaka H, Miura Y, Maekawa T, Saji H, Mimori T, Matsuda F Terao C, Yoshifuji H, Ohmura K, Murakami K, Kawabata D, Yurugi K, Tazaki J, Kinoshita H, Kimura A, Akizuki M, Kawaguchi Y, Yamanaka H, Miura Y, Maekawa T, Saji H, Mimori T, Matsuda F Terao C, Yoshifuji H, Ohmura K, Murakami K, Kawabata D, Yurugi K, Tazaki J, Kinoshita H, Kimura A, Akizuki M, Kawaguchi Y, Yamanaka H, Miura Y, Maekawa T, Saji H, Mimori T, Matsuda F Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Rheumatology (Oxford, England), 52, 10, 1769-1774 Rheumatology (Oxford, England), 52, 10, 1769-1774 Rheumatology (Oxford, England), 52, 10, 1769-1774 2013/10 公開
Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, Shimizu M, Kawaguchi T, Chen Z, Naruse TK, Sato-Otsubo A, Ebana Y, Maejima Y, Kinoshita H, Murakami K, Kawabata D, Wada Y, Narita I, Tazaki J, Kawaguchi Y, Yamanaka H, Yurugi K, Miura Y, Maekawa T, Ogawa S, Komuro I, Nagai R, Yamada R, Tabara Y, Isobe M, Mimori T, Matsuda F Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, Shimizu M, Kawaguchi T, Chen Z, Naruse TK, Sato-Otsubo A, Ebana Y, Maejima Y, Kinoshita H, Murakami K, Kawabata D, Wada Y, Narita I, Tazaki J, Kawaguchi Y, Yamanaka H, Yurugi K, Miura Y, Maekawa T, Ogawa S, Komuro I, Nagai R, Yamada R, Tabara Y, Isobe M, Mimori T, Matsuda F Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, Shimizu M, Kawaguchi T, Chen Z, Naruse TK, Sato-Otsubo A, Ebana Y, Maejima Y, Kinoshita H, Murakami K, Kawabata D, Wada Y, Narita I, Tazaki J, Kawaguchi Y, Yamanaka H, Yurugi K, Miura Y, Maekawa T, Ogawa S, Komuro I, Nagai R, Yamada R, Tabara Y, Isobe M, Mimori T, Matsuda F Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. American journal of human genetics, 93, 2, 289-297 American journal of human genetics, 93, 2, 289-297 American journal of human genetics, 93, 2, 289-297 2013/08 公開
Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database. Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database. Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database. PloS one, 8, 3, e59341 PloS one, 8, 3, e59341 PloS one, 8, 3, e59341 2013 公開
Murakami K, Fujii T, Mimori T Murakami K, Fujii T, Mimori T Murakami K, Fujii T, Mimori T [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: II. Pathophysiology; 3. Autoantibodies in rheumatoid arthritis]. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: II. Pathophysiology; 3. Autoantibodies in rheumatoid arthritis]. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: II. Pathophysiology; 3. Autoantibodies in rheumatoid arthritis]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 101, 10, 2844-2850 Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 101, 10, 2844-2850 Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 101, 10, 2844-2850 2012/10 公開
Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Umehara H, Mimori T Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Umehara H, Mimori T Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Umehara H, Mimori T Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. FEBS letters, 586, 4, 319-324 FEBS letters, 586, 4, 319-324 FEBS letters, 586, 4, 319-324 2012/02 公開
Iguchi-Hashimoto M, Usui T, Yoshifuji H, Shimizu M, Kobayashi S, Ito Y, Murakami K, Shiomi A, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T Iguchi-Hashimoto M, Usui T, Yoshifuji H, Shimizu M, Kobayashi S, Ito Y, Murakami K, Shiomi A, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T Iguchi-Hashimoto M, Usui T, Yoshifuji H, Shimizu M, Kobayashi S, Ito Y, Murakami K, Shiomi A, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals. Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals. Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals. PloS one, 6, 10, e27020 PloS one, 6, 10, e27020 PloS one, 6, 10, e27020 2011 公開
Tanaka M, Murakami K, Ozaki S, Imura Y, Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, Usui T, Masaki Y, Fukushima T, Jin ZX, Umehara H, Mimori T Tanaka M, Murakami K, Ozaki S, Imura Y, Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, Usui T, Masaki Y, Fukushima T, Jin ZX, Umehara H, Mimori T Tanaka M, Murakami K, Ozaki S, Imura Y, Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, Usui T, Masaki Y, Fukushima T, Jin ZX, Umehara H, Mimori T DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-β superfamily proteins. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-β superfamily proteins. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-β superfamily proteins. The FEBS journal, 277, 20, 4278-4289 The FEBS journal, 277, 20, 4278-4289 The FEBS journal, 277, 20, 4278-4289 2010/10 公開
Murakami K, Fujii T, Yukawa N, Yoshifuji H, Kawabata D, Tanaka M, Usui T, Mimori T Murakami K, Fujii T, Yukawa N, Yoshifuji H, Kawabata D, Tanaka M, Usui T, Mimori T Murakami K, Fujii T, Yukawa N, Yoshifuji H, Kawabata D, Tanaka M, Usui T, Mimori T Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Modern rheumatology, 17, 2, 167-170 Modern rheumatology, 17, 2, 167-170 Modern rheumatology, 17, 2, 167-170 2007 公開

  • <<
  • >>
  • 表示
タイトル言語:
Misc
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
村上 孝作, 八木田 正人 村上 孝作, 八木田 正人 村上 孝作, 八木田 正人 代謝性疾患を持つ関節リウマチ・脊椎関節炎の診療上の留意点と治療選択 【代謝性疾患は炎症性疾患の活動性を増悪させていると認識し、薬剤特性を考えて治療に臨む】 代謝性疾患を持つ関節リウマチ・脊椎関節炎の診療上の留意点と治療選択 【代謝性疾患は炎症性疾患の活動性を増悪させていると認識し、薬剤特性を考えて治療に臨む】 代謝性疾患を持つ関節リウマチ・脊椎関節炎の診療上の留意点と治療選択 【代謝性疾患は炎症性疾患の活動性を増悪させていると認識し、薬剤特性を考えて治療に臨む】 日本医事新報, 4858, 56-56 日本医事新報, 4858, 56-56 日本医事新報, 4858, 56-56 2017/06 日本語 公開
村上 孝作 村上 孝作 村上 孝作 Specialized pro-resolving lipid mediator(SPM)による関節炎およびリウマチ性疾患制御の可能性 Specialized pro-resolving lipid mediator(SPM)による関節炎およびリウマチ性疾患制御の可能性 Specialized pro-resolving lipid mediator(SPM)による関節炎およびリウマチ性疾患制御の可能性 日本臨床免疫学会会誌, 39, 3, 155-163 日本臨床免疫学会会誌, 39, 3, 155-163 日本臨床免疫学会会誌, 39, 3, 155-163 2016/06 日本語 公開
新宅 雅幸, 村上 孝作, 堤 寛 新宅 雅幸, 村上 孝作, 堤 寛 新宅 雅幸, 村上 孝作, 堤 寛 劇症肝炎類似の病像を呈したWeil病の1剖検例 劇症肝炎類似の病像を呈したWeil病の1剖検例 劇症肝炎類似の病像を呈したWeil病の1剖検例 日本病理学会会誌, 102, 1, 469-469 日本病理学会会誌, 102, 1, 469-469 日本病理学会会誌, 102, 1, 469-469 2013/04 日本語 公開
村上 孝作, 藤井 隆夫, 三森 経世 村上 孝作, 藤井 隆夫, 三森 経世 村上 孝作, 藤井 隆夫, 三森 経世 【関節リウマチ(RA):診断と治療の進歩】 病態 自己抗体 【関節リウマチ(RA):診断と治療の進歩】 病態 自己抗体 【関節リウマチ(RA):診断と治療の進歩】 病態 自己抗体 日本内科学会雑誌, 101, 10, 2844-2850 日本内科学会雑誌, 101, 10, 2844-2850 日本内科学会雑誌, 101, 10, 2844-2850 2012/10 日本語 公開
村上 孝作, 三森 経世 村上 孝作, 三森 経世 村上 孝作, 三森 経世 【関節リウマチ診療update-これだけは知っておきたい知識とは?】 《診断と病態評価に必要な新たな知識》 関節リウマチの血清学的診断 【関節リウマチ診療update-これだけは知っておきたい知識とは?】 《診断と病態評価に必要な新たな知識》 関節リウマチの血清学的診断 【関節リウマチ診療update-これだけは知っておきたい知識とは?】 《診断と病態評価に必要な新たな知識》 関節リウマチの血清学的診断 内科, 109, 4, 573-576 内科, 109, 4, 573-576 内科, 109, 4, 573-576 2012/04 日本語 公開
藤井 隆夫, 村上 孝作, 橋本 求 藤井 隆夫, 村上 孝作, 橋本 求 藤井 隆夫, 村上 孝作, 橋本 求 【リウマチ性疾患の症候・検査とその鑑別】 リウマトイド因子と抗CCP抗体 【リウマチ性疾患の症候・検査とその鑑別】 リウマトイド因子と抗CCP抗体 【リウマチ性疾患の症候・検査とその鑑別】 リウマトイド因子と抗CCP抗体 リウマチ科, 47, 3, 256-260 リウマチ科, 47, 3, 256-260 リウマチ科, 47, 3, 256-260 2012/03 日本語 公開
藤井 隆夫, 村上 孝作, 橋本 求, 三森 経世 藤井 隆夫, 村上 孝作, 橋本 求, 三森 経世 藤井 隆夫, 村上 孝作, 橋本 求, 三森 経世 2010 ACR/EULAR関節リウマチ新分類基準におけるリウマトイド因子と抗CCP抗体の意義 2010 ACR/EULAR関節リウマチ新分類基準におけるリウマトイド因子と抗CCP抗体の意義 2010 ACR/EULAR関節リウマチ新分類基準におけるリウマトイド因子と抗CCP抗体の意義 リウマチ科, 46, 5, 570-574 リウマチ科, 46, 5, 570-574 リウマチ科, 46, 5, 570-574 2011/11 日本語 公開
細野 祐司, 村上 孝作, 岡田 あかね, 川端 大輔, 野島 嵩樹, 湯川 尚一郎, 大村 浩一郎, 藤井 隆夫, 三森 経世 細野 祐司, 村上 孝作, 岡田 あかね, 川端 大輔, 野島 嵩樹, 湯川 尚一郎, 大村 浩一郎, 藤井 隆夫, 三森 経世 細野 祐司, 村上 孝作, 岡田 あかね, 川端 大輔, 野島 嵩樹, 湯川 尚一郎, 大村 浩一郎, 藤井 隆夫, 三森 経世 ユニキャップエリア抗CCP抗体の臨床的有用性に関する検討 ユニキャップエリア抗CCP抗体の臨床的有用性に関する検討 ユニキャップエリア抗CCP抗体の臨床的有用性に関する検討 医学と薬学, 64, 6, 951-956 医学と薬学, 64, 6, 951-956 医学と薬学, 64, 6, 951-956 2010/12 日本語 公開
村上 孝作, 三森 経世 村上 孝作, 三森 経世 村上 孝作, 三森 経世 早期リウマチ診断基準 早期リウマチ診断基準 早期リウマチ診断基準 日本医事新報, 4479, 92-93 日本医事新報, 4479, 92-93 日本医事新報, 4479, 92-93 2010/02 日本語 公開
中嶋 蘭, 村上 孝作, 三森 経世 中嶋 蘭, 村上 孝作, 三森 経世 中嶋 蘭, 村上 孝作, 三森 経世 【関節リウマチの新しい治療指針】 関節リウマチの基礎知識 診断マーカーの最近の進歩 【関節リウマチの新しい治療指針】 関節リウマチの基礎知識 診断マーカーの最近の進歩 【関節リウマチの新しい治療指針】 関節リウマチの基礎知識 診断マーカーの最近の進歩 整形外科, 59, 8, 844-849 整形外科, 59, 8, 844-849 整形外科, 59, 8, 844-849 2008/07 日本語 公開
村上 孝作, 藤井 隆夫 村上 孝作, 藤井 隆夫 村上 孝作, 藤井 隆夫 【関節リウマチ診療のグローバルスタンダード】 診断のエビデンス 検査は診断・治療にどれだけ役立つ? リウマトイド因子、抗CCP抗体の臨床的意義 【関節リウマチ診療のグローバルスタンダード】 診断のエビデンス 検査は診断・治療にどれだけ役立つ? リウマトイド因子、抗CCP抗体の臨床的意義 【関節リウマチ診療のグローバルスタンダード】 診断のエビデンス 検査は診断・治療にどれだけ役立つ? リウマトイド因子、抗CCP抗体の臨床的意義 EBMジャーナル, 9, 4, 22-26 EBMジャーナル, 9, 4, 22-26 EBMジャーナル, 9, 4, 22-26 2008/06 日本語 公開
村上 孝作, 藤井 隆夫 村上 孝作, 藤井 隆夫 村上 孝作, 藤井 隆夫 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病の診断,治療開始とフォローの実際 成人Still病 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病の診断,治療開始とフォローの実際 成人Still病 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病の診断,治療開始とフォローの実際 成人Still病 Medicina, 45, 1, 100-103 Medicina, 45, 1, 100-103 Medicina, 45, 1, 100-103 2008/01 日本語 公開
村上 孝作, 藤井 隆夫, 三森 経世 村上 孝作, 藤井 隆夫, 三森 経世 村上 孝作, 藤井 隆夫, 三森 経世 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病を疑ったときの診断の進め方 膠原病を疑ったときの検査 リウマトイド因子・抗CCP抗体が陽性・陰性の臨床的意義 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病を疑ったときの診断の進め方 膠原病を疑ったときの検査 リウマトイド因子・抗CCP抗体が陽性・陰性の臨床的意義 【プライマリケア医が主役 膠原病・関節リウマチの早期診断・早期治療】 膠原病を疑ったときの診断の進め方 膠原病を疑ったときの検査 リウマトイド因子・抗CCP抗体が陽性・陰性の臨床的意義 Medicina, 45, 1, 64-67 Medicina, 45, 1, 64-67 Medicina, 45, 1, 64-67 2008/01 日本語 公開
村上 孝作, 三森 経世 村上 孝作, 三森 経世 村上 孝作, 三森 経世 【整形外科医のためのcareとcure I RAのwindow of opportunityを逃さないために】 整形外科医のためのRA診断 早期診断のための抗環状シトルリン化ペプチド(CCP)抗体 【整形外科医のためのcareとcure I RAのwindow of opportunityを逃さないために】 整形外科医のためのRA診断 早期診断のための抗環状シトルリン化ペプチド(CCP)抗体 【整形外科医のためのcareとcure I RAのwindow of opportunityを逃さないために】 整形外科医のためのRA診断 早期診断のための抗環状シトルリン化ペプチド(CCP)抗体 骨・関節・靱帯, 20, 10, 975-982 骨・関節・靱帯, 20, 10, 975-982 骨・関節・靱帯, 20, 10, 975-982 2007/10 日本語 公開

  • <<
  • >>
  • 表示
タイトル言語:
講演・口頭発表等
タイトル タイトル(日本語) タイトル(英語) 会議名 会議名(日本語) 会議名(英語) 主催者 主催者(日本語) 主催者(英語) 開催年月日 記述言語 会議種別 公開
関節リウマチ患者における血漿中脂肪酸プロファイルの検討 関節リウマチ患者における血漿中脂肪酸プロファイルの検討 LIPID PROFILING OF PLASMA IN RHEUMATOID ARTHRITIS PATIENTS BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ヨーロッパリウマチ学会議 ヨーロッパリウマチ学会議 Annual European Congress of Rheumatology 2017/06/15 英語 ポスター発表 公開
タイトル言語:
学術賞等
賞の名称(日本語) 賞の名称(英語) 授与組織名(日本語) 授与組織名(英語) 年月
JCR-EULAR若手リウマチ医トレーニングプログラム2013(長期) JCR-EULAR Young Rheumatologist Training Program 日本リウマチ学会 Japan College for Rheumatology 2012/06/30
外部資金:競争的資金・科学研究費補助金
種別 代表/分担 テーマ(日本語) テーマ(英語) 期間
科学研究費補助金(若手研究B) 代表 脂質分子の炎症収束効果を基盤とした関節リウマチ新規薬剤の開発 2015/04/01〜2017/03/31
若手研究(B) 代表 脂質分子の炎症収束効果を基盤とした関節リウマチ新規薬剤の開発 (平成27年度分) 2015/04/01〜2016/03/31
若手研究(B) 代表 脂質分子の炎症収束効果を基盤とした関節リウマチ新規薬剤の開発 (平成28年度分) 2016/04/01〜2017/03/31
基盤研究(C) 代表 関節リウマチの治療応用を目標とした炎症収束性脂質因子及び受容体の機能解析 (平成29年度分) 2017/04/01〜2018/03/31
難治性疾患等政策研究事業(難治性疾患政策研究事業) 分担 (平成29年度分) 2017/04/01〜2018/03/31
難治性疾患等政策研究事業(難治性疾患政策研究事業) 分担 (平成30年度分) 2018/04/01〜2019/03/31
基盤研究(C) 代表 関節リウマチの治療応用を目標とした炎症収束性脂質因子及び受容体の機能解析 (平成30年度分) 2018/04/01〜2019/03/31